Editorial: The glutamate hypothesis of mood disorders: Neuroplasticity processes, clinical features, treatment perspectives
暂无分享,去创建一个
[1] G. Hasler,et al. The neuroprotective and neuroplastic potential of glutamatergic therapeutic drugs in bipolar disorder , 2022, Neuroscience & Biobehavioral Reviews.
[2] J. Moncrieff,et al. The serotonin theory of depression: a systematic umbrella review of the evidence , 2022, Molecular Psychiatry.
[3] K. Lohr,et al. Defining treatment‐resistant depression , 2020, Depression and Anxiety.
[4] E. Ballard,et al. The Kynurenine Pathway and Bipolar Disorder: Intersection of the Monoaminergic and Glutamatergic Systems and Immune Response , 2019, Molecular Psychiatry.
[5] J. Krystal,et al. Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeutics. , 2015, Annual review of medicine.
[6] W. Drevets,et al. Discovering Endophenotypes for Major Depression , 2004, Neuropsychopharmacology.
[7] R. Salomon,et al. Lack of behavioral effects of monoamine depletion in healthy subjects , 1997, Biological Psychiatry.
[8] M. Fava,et al. Definition and epidemiology of treatment-resistant depression. , 1996, The Psychiatric clinics of North America.